Mikael Mandrup Egebjerg
Mikael Mandrup Egebjerg has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Gitte Ravn-Haren
National Food Institute, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark
4 shared publications - Kirsten Pilegaard
Division of Toxicology and Risk Assessment, National Food Institute, Technical University of Denmark, Søborg, Denmark
4 shared publications - Lea Bredsdorff
Technical University of Denmark, National Food Institute, Mørkhøj Bygade 19, DK-2860 Søborg, Denmark
4 shared publications - Anoop Kumar Sharma
Research Group for Chemical Risk Assessment and GMO, Technical University of Denmark, National Food Institute, Lyngby, Denmark
2 shared publications - Elsa Nielsen
Division of Diet, Disease Prevention and Toxicology, National Food Institute, Technical University of Denmark, Kgs. Lyngby, DK-2800, Denmark
2 shared publications Folmer D. Eriksen
National Food Institute, Technical University of Denmark, Kemitorvet, Building 201, DK-2800, Kgs. Lyngby, Denmark
2 shared publications
Latest Publications
- Top Cited Papers
- 20 April 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (8) , 648-662
Safety considerations for cereblon-recruiting targeted protein degraders
Targeted protein degraders (TPDs) that recruit the E3 ligase cereblon (CRBN) include two innovative drug classes: molecular glue degraders and proteolysis targeting chimeras. These TPDs have shown great promise in addressing difficult drug targets in oncologic and non-oncologic diseases; however, as well as inducing proteosomal degradation of their therapeutic target, they can also lead to degradation of unintended CRBN neosubstrates. This is a major safety consideration because many CRBN-recruiting TPDs are structurally related to thalidomide and other immunomodulatory imide drugs that are known to be teratogenic. The teratogenic effect of immunomodulatory imide drugs is due in part to their induction of CRBN-mediated neosubstrate degradation. Therefore, there is a need for a scientific consensus on rigorous, consistent and effective methods to assess the safety of CRBN-recruiting TPDs. Here, we provide an overview of the endogenous functions and substrates of CRBN as well as of the role of CRBN as the effector of immunomodulatory imide drugs, next-generation molecular glue degraders and proteolysis targeting chimeras. We discuss how degradation of unintended 'off-target' CRBN neosubstrates could potentially cause toxicity or safety liabilities in multiple organ systems as well as induce teratogenic effects. We outline key safety considerations for the development of CRBN-recruiting TPDs and suggest best practices for monitoring on-target versus off-target degradation.
- 20 April 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (8) , 648-662
Top Cited PapersSafety considerations for cereblon-recruiting targeted protein degraders
Targeted protein degraders (TPDs) that recruit the E3 ligase cereblon (CRBN) include two innovative drug classes: molecular glue degraders and proteolysis targeting chimeras. These TPDs have shown great promise in addressing difficult drug targets in oncologic and non-oncologic diseases; however, as well as inducing proteosomal degradation of their therapeutic target, they can also lead to degradation of unintended CRBN neosubstrates. This is a major safety consideration because many CRBN-recruiting TPDs are structurally related to thalidomide and other immunomodulatory imide drugs that are known to be teratogenic. The teratogenic effect of immunomodulatory imide drugs is due in part to their induction of CRBN-mediated neosubstrate degradation. Therefore, there is a need for a scientific consensus on rigorous, consistent and effective methods to assess the safety of CRBN-recruiting TPDs. Here, we provide an overview of the endogenous functions and substrates of CRBN as well as of the role of CRBN as the effector of immunomodulatory imide drugs, next-generation molecular glue degraders and proteolysis targeting chimeras. We discuss how degradation of unintended 'off-target' CRBN neosubstrates could potentially cause toxicity or safety liabilities in multiple organ systems as well as induce teratogenic effects. We outline key safety considerations for the development of CRBN-recruiting TPDs and suggest best practices for monitoring on-target versus off-target degradation.
- 1 March 2019
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 125, 631-632
Response to comment on article, doi.org/10.1016/j.fct.2018.12.055
- 1 March 2019
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 125, 631-632
Response to comment on article, doi.org/10.1016/j.fct.2018.12.055
- 1 October 2018
- Published by Elsevier in Toxicology Letters
- Vol. 295, S176
Risk assessment of formaldehyde present in food and drinking water
- 1 October 2018
- Published by Elsevier in Toxicology Letters
- Vol. 295, S176
Risk assessment of formaldehyde present in food and drinking water
- 1 October 2018
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 120, 129-142
Are wild and cultivated flowers served in restaurants or sold by local producers in Denmark safe for the consumer?
- 1 October 2018
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 120, 129-142
Are wild and cultivated flowers served in restaurants or sold by local producers in Denmark safe for the consumer?
- 12 September 2018
- Published by Elsevier in Toxicology Letters
- Vol. 295, S140
Safety evaluation of plants collected from the wild served as food in Danish restaurants
- 12 September 2018
- Published by Elsevier in Toxicology Letters
- Vol. 295, S140
Safety evaluation of plants collected from the wild served as food in Danish restaurants
- 1 February 2018
- Published by Wiley in EFSA Supporting Publications
- Vol. 15 (2)
Extensive literature search for studies related to fumonisins and their modified forms
- 1 February 2018
- Published by Wiley in EFSA Supporting Publications
- Vol. 15 (2)
Extensive literature search for studies related to fumonisins and their modified forms